A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES
A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES
A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES
Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine
作者: Pandha, H. ; Dalgleish, A. G. ; Quatan, N. ; Michael, A. ; Wushishi, F.
4726 Background: We have shown previously that immunization with ONY-P1, a whole cell vaccine comprising 3 irradiated allogeneic prostate cancer cell lines, markedly increased time to disease progr...